Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal Bupivacaine vs Peripheral Nerve Block for Ankle and Hindfoot Surgery
NCT03922620Phase 4Terminated
- Sponsor
- Geisinger
- Start
- Jan 2020
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of liposomal bupivacaine in acute pain (2 arms), sponsored by Geisinger. Primary endpoint: Visual Analog Scale at 6 weeks. Started Jan 2020; status: terminated.
02
Drugs
liposomal bupivacaine
03
Conditions
acute pain
Beyond the preview
Go deeper on NCT03922620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03922620.